Full-Time
Brand Manager Oncology
Oncology
Posted on 6/17/2026
AstraZeneca
10,001+ employees
Global pharmaceutical company developing prescription medicines
No salary listed
Dubai - United Arab Emirates
In Person
 Growth & Marketing |
|---|
- Bachelor’s degree in relevant field (e.g. Pharmaceuticals or science)
- For Internal Candidates: Minimum 5 years of Experience in pharmaceutical industry, with at least one year in AstraZeneca.
- For External Candidates: Minimum 2 years of experience in pharmaceutical marketing roles in Oncology/ Specialty care in Gulf.
- Develops and/or facilitates the development and creation of the promotional plan and programs and ensure their consistency with the brand strategy.
- Develops and manages the promotion /communication budget and project timelines.
- Collaborates with brand team to make a convincing case for appropriate budget and expectations for marketing opportunities.
- Maintains awareness of competitive activity in consumer marketing
- Manages overall relationships with advertising agencies and other vendors.
- Responsible for the implementation of promotional/communication strategies, plans and programs in support of brand strategies and objectives.
- Provides input into Communication Planning and Operational Planning
- Strategic Thinking: Develop short & long-term brand strategies.
- Communication Skills: Engage effectively with internal & external stakeholders.
- Project Management: Organize and manage multiple projects to align with brand objectives.
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Your Connections
People at AstraZeneca who can refer or advise you
Simplify's Take
What believers are saying
- PTEN companion diagnostics create a clearer precision-oncology launch path.
- Elecoglipron could broaden AstraZeneca into obesity, diabetes, cardiovascular, and kidney care.
- TROP2 biomarker collaboration strengthens computational pathology for targeted lung-cancer selection.
What critics are saying
- Biomarker-restricted Truqap growth depends on reimbursement and PTEN testing adoption.
- Elecoglipron faces high phase III execution risk after only mid-stage validation.
- TRUQAP safety signals, especially hyperglycemia, limit use in fragile oncology patients.
What makes AstraZeneca unique
- AstraZeneca combines Swedish roots and UK headquarters with dual R&D leadership.
- Truqap gained June 2026 FDA approval for PTEN-deficient metastatic prostate cancer.
- Elecoglipron advanced as an oral GLP-1 with phase IIb weight-loss and HbA1c data.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 2%Sustainable pharma packaging starts with asking better questions. Cambridge Design Partnership were delighted to see AstraZeneca and Deloitte nominated for an MCA Award for their work on sustainable pharmaceutical packaging. Cambridge Design Partnership supported the project through its materials science and manufacturing teams. It is a strong example of what Cambridge Design Partnership see with large pharmaceutical clients: sustainable packaging is a product development challenge, not a side issue about greener materials. The project focused on moving towards fully recyclable blister packaging. Three requirements shaped the work: recyclability, barrier performance and ease of manufacture, all in a regulated market where drug performance and patient safety matter. That combination shows why pharmaceutical packaging forces Cambridge Design Partnership to ask better questions. A greener material can still be the wrong answer. The narrow question is, "Can we make this pack recyclable?" The better question is, "What has to be true for a more sustainable pack to work in the real world?" That moves clients from material preference to product evidence. A material cannot be judged by its specification alone, or by whether it is recyclable, bio-based, fiber-based or lower carbon. It has to protect the medicine, run on packaging lines, survive transport and storage, meet regulatory expectations, support credible claims and work in the waste and recycling systems where it is sold. Sustainable pharma packaging is not a material swap. It is a system design challenge. Supplier data is not product evidence. The narrow question is, "Is this material more sustainable?" The better question is, "Will this material still protect the medicine after we process it, seal it, pack it and ship it?" A supplier may present a laminate, film, coating or fiber-based structure with strong barrier data, valid and given in good faith. But it usually describes the material under laboratory test conditions, not after forming, sealing, printing, sterilization, filling, transit and storage. Once a material enters a commercial process, barrier performance can fall, seals can become inconsistent, moisture protection can become marginal, and machinability can create scrap. The supplier is describing the material. The development team has to prove the pack. That moves thinking from material preference to product evidence. A material cannot be judged by its specification alone, or by whether it is recyclable, bio-based, fiber-based or lower carbon. It has to protect the medicine, run on packaging lines, survive transport and storage, meet regulatory expectations, support credible claims and work in the waste and recycling systems where it is sold. Sustainable pharma packaging is not a material swap. It is a system design challenge. The current pack may be over-specified. Patient safety is not negotiable. But that does not mean the current pack should always be copied. The narrow question is, "Can the new pack match the existing pack?" The better question is, "What pack performance does this medicine actually need?" With over 25 years working with leading pharmaceutical companies, you soon learn that packs are often based on specifications set years ago. Some requirements are essential. Others may reflect old material choices, equipment limits, qualification decisions or requirements that have not been reviewed for a long time. There is also a practical reason legacy formats stay in place. Changing a pharmaceutical pack can create cost, project risk and, in some cases, the need for regulatory approval or updated filings. That risk is real. But it is also why the requirement needs to be clear before change is ruled in or out. That does not mean organizations should lower standards. It means defining the real requirement: barrier performance, shelf life, safety margins, sterility and sustainability all needs to be considered and understood. Not every sustainability opportunity is worth pursuing. In many of its projects, the useful starting point is not one problem material. It is the portfolio. The narrow question is, "Which material should we replace?" The better question is, "Which change is worth pursuing?" Which formats create the most material burden? Which markets create the greatest regulatory exposure? Which SKUs use more packaging than the protection need justifies? Which changes affect validation or line performance? Which products should be left alone because the benefit is too small or the risk is too high? That portfolio view matters because the cost of change is real. Packaging lines are optimized, validated and expensive to alter. Changing equipment, requalifying a process or updating a specification can take months if notyears and require major investment. A material that cannot run at line speed is not a solution. A pack that improves end-of-life performance but creates stability or validation risk is not a solution. Recyclable in theory is not enough. The narrow question is, "Is this pack recyclable?" The better question is, "Will this pack actually be collected, sorted and recycled in the market where it is sold?" For global brands, a pack may be recyclable in one country, misunderstood in another and incinerated in a third. It may need separation steps patients will not perform, or use coatings, adhesives, inks, labels or mixed components that reduce the value of the recovered stream. It may be too small, contaminated, complex or unfamiliar for the sorting system. Designing for end-of-life means working backwards from real infrastructure: patient behavior, local collection, sorting, recycler tolerance and the actual route in each market. If that chain breaks, the intended environmental benefit may never appear. Waiting for regulation is already too late. The EU Packaging and Packaging Waste Regulation is moving packaging towards clearer requirements for recyclability, labeling, waste management and evidence. Healthcare and contact-sensitive packaging has specific treatment because patient protection matters. But that should not be read as permission to wait. Pharmaceutical packaging changes can take years. If a change affects barrier properties, stability, sterility, line performance or regulatory filings, the timescale expands quickly. The narrow question is, "What does regulation require next year?" The better question is, "What packaging choices are we making now that will still be in market when regulation, infrastructure and procurement expectations have moved on?" Leadership starts with the better question. It's great to see this its Astra Zeneca and Deloitte collaboration project recognized with a nomination but it is equally important to recognize that the best consultancy projects begin with the client challenge. Real progress starts when companies identify the challenges that need solving and ask the right questions. AstraZeneca has consistently done that on sustainability, creating the impetus for work like this and driving the search for practical solutions. This work on blister packs is just one element of AstraZeneca's wider sustainability program. The company has set a goal of 50% waste circularity by 2030 and is already applying circular thinking across the business: from liquid helium reuse to silica waste reduction and its Turbuhaler take-back scheme in Sweden. That is leadership in pharmaceutical sustainability. At the heart of CDP's approach: how to turn sustainability ambition into real products. Connect with CDP. For more on how to accelerate meaningful innovation in sustainable pharmaceutical packaging, contact Cambridge Design Partnership.
AstraZeneca joins ZERO Prostate Cancer's historic 'blitz the barriers' initiative as a founding partner. June 15, 2026 DCBN news, syndication comments off on astrazeneca joins ZERO Prostate Cancer's historic 'blitz the barriers' initiative as a founding partner. Partnership Aims To Save 100,000 Lives by Closing the Prostate Cancer Survival Gap In Highest-Risk Communities ALEXANDRIA, Va., June 15, 2026 /PRNewswire/ - ZERO Prostate Cancer, the nation's leading prostate cancer organization dedicated to advocacy, awareness, education, and support,...
Mitie awarded £26 million contract with AstraZeneca. * Mitie has secured a new £26 million contract at AstraZeneca's Macclesfield campus in Cheshire * The contract will see Mitie deliver mechanical and electrical maintenance, reactive engineering services and energy management * The partnership includes a focus on people and skills, with investment in apprenticeships, training and long-term workforce development Mitie has secured a new contract with AstraZeneca at its Macclesfield campus in Cheshire, a major UK biopharmaceutical manufacturing, research and technology site. This builds on Mitie's expertise managing complex, safety-critical and highly regulated environments, including pharmaceutical manufacturing. Mitie will deliver a range of engineering and energy services, including mechanical and electrical maintenance, reactive engineering support and energy management and optimisation, helping to maintain equipment reliability and support the day-to-day operation of the site. As part of the contract, Mitie will provide clear and consistent visibility of energy use and associated carbon emissions across the Macclesfield site. Using data captured through Mitie's Orbit platform, its energy management and analytics system, energy performance will be continuously monitored to inform practical improvements to how the site is run. Alongside this, Mitie will invest in training, mentoring and skills pathways, welcoming a number of new apprentices, and committing more than 1,300 hours of volunteering each year. These initiatives will support community, education and environmental projects delivered in collaboration with AstraZeneca. Sam White, Managing Director, Technical Services, Mitie, said: "Mitie Group plc. is proud to bring its engineering expertise and energy insight to deliver services for AstraZeneca that support operational reliability and sustainability, both now and into the future. "By investing in skills, apprenticeships and community initiatives, this partnership will support a resilient, future-ready workforce at the Macclesfield campus." Notes to editors. About Mitie: The Future of High Performing Places Founded in 1987, Mitie employs 90,000 colleagues and is the leading technology-led Facilities Management, Transformation and Compliance company in the UK. Mitie Group plc. is a trusted partner to around 3,000 customers across the public and private sectors, working with them to transform their built estates, and the lived experience for their colleagues and customers, as well as providing data-driven insights to inform better decision-making. In each of its core services of engineering (hard services) and security and hygiene (soft services) Mitie Group plc. hold market leadership positions. Mitie Group plc. also deliver transformational projects in the areas of power and grid connections, building fit outs & modernisation, decarbonisation, fire safety & security and telecoms infrastructure, alongside compliance capabilities in fire safety & security and environmental services. Its sector expertise includes central government, critical national infrastructure, defence, financial services, healthcare & life sciences, local government & education, retail & logistics, manufacturing & media and transport & aviation. Mitie Group plc. hold industry-leading ESG credentials, including a place on the CDP Climate change A List, and Mitie Group plc. has received multiple awards including Best Low Carbon Solution and Net Zero Carbon Strategy of the year. Mitie Group plc. has validated science-based targets that support its ambitions to reach Net Zero. Mitie Group plc. has been recognised as a UK Top Employer for the seventh consecutive year and Most Admired Company in the Support Services sector. Mitie Group plc. is also ranked 16th in the Top 100 Apprenticeship employers and ninth in the Inclusive Top 50 UK Employers list. Find out more at www.mitie.com
* home * latest news * press releases * AstraZeneca announces opening of new API manufacturing facility in Dublin. AstraZeneca announces opening of new API manufacturing facility in Dublin 30/04/2026 Ireland AstraZeneca today officially opened their new Active Pharmaceutical Ingredient (API) manufacturing facility in Dublin. This new facility demonstrates how advanced automation, AI, and innovative new technologies push the boundaries of science and manufacturing. It was developed with the support and collaboration of Ireland's investment agency, IDA Ireland. Taoiseach Micheál Martin said: "Investments like this state-of-the-art new manufacturing facility strengthen our healthcare and biopharma base, support high-quality employment, and help ensure medicines can be supplied to patients around the world. It is a significant vote of confidence in Ireland's life sciences ecosystem and in the highly skilled people who work across the sector. I warmly welcome AstraZeneca's continued commitment to Dublin and I commend IDA Ireland for its ongoing work in supporting and securing investments of this scale." Pam Cheng, Executive Vice President, Global Operations, IT & Chief Sustainability Officer, AstraZeneca said: "This cutting-edge API Commercialisation facility is an innovative and unique asset in its global operations network, and plays a key role in the development and launch of its new medicines across its oncology portfolio and beyond. Through advanced automation, AI and innovative new technologies, IDA Ireland is pushing the boundaries of science and manufacturing - enhancing speed, flexibility, and sustainability to deliver future therapies to patients. Thank you to all colleagues and partners for making this milestone a reality." Michael Lohan, CEO of IDA Ireland said: "Healthcare and biopharma remain a key growth driver within IDA Ireland's strategy, and investments like this new API facility underline Ireland's strength in advanced manufacturing, innovation and talent. We are delighted to support AstraZeneca as it continues to expand its operations in Dublin, creating high-value jobs and strengthening the resilience of global supply chains while delivering life-changing medicines for patients worldwide." You might also be interested in. West continues its investment in Ireland with Dublin manufacturing facility expansion. West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced an additional 330 roles as part of an expansion of its manufacturing site in Damastown, Dublin. West is supported by the Irish Government, through IDA Ireland. Novartis and Deciphex host roundtable about Ireland's AI sector to mark collaboration. Collaboration Between Novartis and Deciphex Harnesses AI For Drug Discovery and Development.
Ailux appoints Maria Belvisi, Ph.D., as Chief Scientific Officer. Apr 09, 2026, 20:00 ET * Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investment decision - a program that recently delivered landmark wins in two pivotal COPD trials * Her appointment accelerates Ailux's evolution from AI-native biologics discovery into a fully integrated drug development organization, targeting first clinical entry by 2027 * Professor Belvisi will lead Ailux's scientific strategy and new program development, and will establish and lead a UK research site to complement Ailux's Shanghai research capabilities. SHANGHAI and LONDON, April 9, 2026 /PRNewswire/ - Ailux, an AI-native biotech company discovering and engineering next-generation biologics across multiple indications, today announced the appointment of Maria G. Belvisi, Ph.D. as Chief Scientific Officer. Professor Belvisi brings more than three decades of industry and academic leadership in drug research and development, including nearly a decade at AstraZeneca where she served as Senior Vice President, Research and Development, Respiratory & Immunology, BioPharmaceuticals R&D. She will report to Alex Li, Chief Executive Officer of Ailux. Ailux is an AI-native biotech company headquartered in Shanghai, founded within and wholly-owned by XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab and a global team of approximately 150 across China, the UK, and the US. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is advancing its internal pipeline toward first clinical entry by 2027. Professor Belvisi joined AstraZeneca in 2017 and was accountable for the global Respiratory & Immunology R&D organization spanning approximately 500 scientists across the UK, Sweden, the US, and Spain. During her tenure she built and advanced one of the industry's most innovative and productive early R&I portfolios, with end-to-end responsibility from target identification through Phase 3 investment decisions. Most recently, tozorakimab - a potential first-in-class IL-33 antibody that she championed from early preclinical development through the Phase 3 investment decision - met its primary endpoints in both the OBERON and TITANIA trials in COPD. The results, announced last month, have been widely recognized as landmark for the field and potentially transformational for COPD patients. Alongside her industry career, Maria has held a professorship at the National Heart & Lung Institute, Imperial College London - a position she continues to hold today. During her time leading the Imperial research group, she trained more than thirty PhD students and published over 250 peer-reviewed papers. She also served as Research Director of the European Respiratory Society (2013-2016) and founded IR Pharma, a contract research organization serving major pharmaceutical companies in the respiratory space. In her new role at Ailux, Maria will also establish and lead a UK research site, further expanding the company's presence in one of the world's leading centers for biomedical research and innovation. She is a Fellow of the European Respiratory Society, the British Pharmacological Society, and the Academy of Medical Sciences, and was named one of Endpoints News' "20 Outstanding Women in Biopharma" in 2021. "Maria is exactly the kind of scientific leader Ailux needs at this stage of our journey," said Alex Li, CEO of Ailux. "She has spent her career turning bold scientific hypotheses into medicines that reach patients - building programs from scratch, taking them through the clinic, and doing so at a scale that few have matched. We are building Ailux to go the full distance, and Maria's scientific leadership will be central to every step of that journey." "What drew me to Ailux is the genuine integration of AI and biology - not AI as a tool applied to conventional drug discovery, but as a co-equal foundation for how programs are conceived and built," said Professor Belvisi, CSO of Ailux. "I believe Ailux's platform and team give us a real opportunity to originate first-in-class and best-in-class medicines, and I am excited to join the team and work together to build a global company that can deliver transformative therapies to patients." About Ailux Ailux is an AI-native biotech company headquartered in Shanghai and a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in building the AI & robotics infrastructure for life sciences and beyond. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company's global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027. SOURCE Ailux